John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.

Articles by John Carroll

Anal cancer vax gets FDA green light

Merck has won approval for a new indication of its HPV vaccine Gardasil. The FDA gave its OK to start selling Gardasil to prevent anal cancer. Investigators presented data demonstrating that Gardasil

Vical touts animal study of vax adjuvant

Vical announced today that the company's Vaxfectin adjuvant significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents

FDA lifts hold on Novavax RSV vaccine trial

Shares of Novavax ($NVAX) surged this morning on the news that the FDA has lifted its clinical hold on a Phase I study of an experimental RSV vaccine. Back in November the biotech reported that it

Single therapeutic vaccine has potential to fight multiple conditions

A translational team of experts in Europe say they have identified a protein which is produced naturally in the human body and can be used as a therapeutic vaccine capable of fighting a range of

Replica vaccine offers new strategy in fight against polio

Backed with funds from the Bill and Melinda Gates Foundation, an international team of top vaccine researchers has come together to explore the potential of a new type of polio vaccine that "tricks"

Merck joins PATH on next-gen malaria vax program

Merck ($MRK) has signed on to work with the groundbreaking PATH Malaria Vaccine Initiative and the NYU Langone Medical Center on a next-generation malaria vaccine that will attempt to ward off the

Fauci outlines R&D challenges to universal flu vaccine

Developing a universal flu shot is one of the Holy Grails of the vaccine industry. But the long research road to the marketplace will be long and littered with challenging hurdles, according to

Breakthrough meningitis vaccine costs only 50 cents a jab

Working with money from the Bill and Melinda Gates Foundation, a team of experts from Seattle-based PATH and the World Health Organization were able to develop a new vaccine for meningitis that costs

WikiLeaks spotlights secret catalog of vulnerable vax facilities

During the recent swine flu pandemic, U.S. officials were bitterly frustrated by the need to rely on foreign vaccine makers to supply the bulk of the flu shots needed to calm an initially panicked

Wary J&J says it may be forced to renegotiate Crucell buyout

J&J has made it crystal clear that it still wants to complete its planned buyout of the Dutch biotech Crucell. But despite its hunger to build a major vaccine initiative on the foundation of the